INS and type 1 diabetes mellitus: Consistent with being a Kv1.3 inhibitor, SD effectively reduces islet β cell damage in a rodent model of STZ-induced type I diabetes and increases levels of plasma insulin, thereby lowering blood glucose [10], suggesting that SD has a therapeutic effect on autoimmune diseases.